PARPi and Ovarian Cancer Survival
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-80
SponsorShanghai Gynecologic Oncology Group
About this trial
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
Complete data on first-line treatment and maintenance therapy.
Availability of follow-up data.
Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
Disqualifiers
Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
Missing first-line or follow-up data.
Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
Patients with second relapse.
Trial population
Patients who were newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer or had platinum-sensitive first relapsed ovarian cancer between December 2013 and December 2024.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
6,000 Participants
are grouped into 2 trial groupsGroup A: Patients with newly diagnosed advanced epithelial ovarian cancer
Group B: Patients with platinum-sensitive first relapsed epithelial ovarian cancer
Trial outcomes
Primary outcomes
1
Overall Mortality
Mortality of any cause
Time frame
11 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Shanghai Gynecologic Oncology Group
Lead sponsor
Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China
Collaborator
Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Collaborator
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University
Collaborator
Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: